FDA Warns of Liver Injury Risk with Tolvaptan MedPage Today But, the company said, "these data are not adequate to exclude the possibility that patients receiving Samsca for its indicated use of clinically significant hypervolemic and euvolemic hyponatremia are at a potentially increased risk for irreversible ...
No comments:
Post a Comment